CAR-T Cell Therapy as Potential Venue for Multiple Myeloma - Bispecific Antibody may provide immuno-oncology in safer venue

CAR-T Cell Therapy as Potential Venue for Multiple Myeloma - Bispecific Antibody may provide immuno-oncology in safer venue

User Photo
ASHReport

3 years
172 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Joshua Richter, MD from John Theurer Cancer Center discusses CAR-T Cell therapy as potential venue for multiple myeloma and bispecific antibody may provide immuno-oncology in safer venue at the 2017 American Society of Hematology.

Up Next Autoplay
>